Abstract: Anti-IL13Ra2 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, and/or autoimmune disease.

Abstract: The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.

Abstract: Anti-DLL3 antibodies and antigen-binding fragments thereof, anti-CD47 antibodies and antigen-binding fragments thereof, and anti-CD47/DLL3 bispecific antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Described herein are methods for treating a subject with an aneurysm or a dissection in a blood vessel comprising administering to the subject an effective amount of a ?-hydroxybutyrate. The methods described herein are useful in repairing damage to arteries caused by an aneurysm. Additionally, described herein are methods for reducing or preventing the risk of the formation of aneurysm or dissection in a blood vessel comprising administering to the subject an effective amount of a ?-hydroxy butyrate.

Abstract: Disclosed are a calibration method and apparatus for a coherent light module, and a computer-readable storage medium. The method comprises: obtaining a first and second curve relationship respectively representing a relationship between a power-gain monitoring voltage and optical power of a receiver of the coherent optical module and a relationship between a target setting voltage and the optical power of the receiver in the optical power range of the receiver; determining first optical power based on the first and second curve relationship, which is used for dividing the optical power range of the receiver into two ranges; and determining a calibration mode of the coherent light module based on the first optical power, which comprises: calibrating the coherent light module by using the first curve relationship or the second curve relationship when the optical power of the receiver is in a first range or in a second range.

Abstract: Anti-DLL3 antibodies and antigen-binding fragments thereof, anti-CD47 antibodies and antigen-binding fragments thereof, and anti-CD47/DLL3 bispecific antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Engineered bispecific antibodies with charge pairs introduced at the interface of CHI and CL alone or in combination with other charge pairs at the interface of VH and VL are described. Also described are anti-CD47/anti-CLDN18.2 and anti-CD3/anti-DLL3 bispecific antibodies and antigen-binding fragments thereof. Also described are nucleic acids encoding the bispecific antibodies, compositions comprising the bispecific antibodies, and methods of producing the bispecific antibodies and using the bispecific antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Described are an encoding method and system for ROAs. The encoding method includes the following steps: given a set of authorized IP prefixes an AS which are maintained with an IP address trie. By specifying a sequence of hanging levels on the IP address trie, it is divided into a set of non-overlapping sub-trees, each rooted at a hanging level. A node on a hanging level uniquely defines a sub-tree rooted at it, whose prefix can be encoded as the identifier of this sub-tree. All authorized prefixes covered by a sub-tree can be encoded into a bitmap of 2h bits, where h is the height of this sub-tree. Thus, the set of authorized IP prefixes of an AS is encoded into several tuples (identifier, bitmap).

Abstract: The knob screen device includes a glass touch cover plate, a display screen, a screen support frame, a semi-transparent turning structure, an annular light-leading friction shim, at least one battery, a mainboard and a magnetic attraction assembly. The knob screen device further comprises: at least one Hall sensor provided on the mainboard; at least one multicolor LED ambient light provided on the mainboard; and at least one annular multipolar flexible magnet provided in the semi-transparent turning structure. The semi-transparent turning structure is connected to external component by means of the magnetic attraction assembly. In this way, the knob screen device is simple in structure, low in cost, easy to process and install and more flexible in application circumferences.

Abstract: Anti-FOLR1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.